A volatile stock market, trade war uncertainty, and rising recession fears have frozen IPOs and rattled venture capital.

That’s spelling trouble for venture capital, with major tech unicorns already delaying plans to go public due to tech stocks ...

SGX could see more IPOs from firms in markets hit harder by US President Donald Trump's tariffs. Read more at ...

Tech companies like Klarna and StubHub were set to make their stock market debuts. Instead, IPOs are the latest victim of ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

Some companies planning to list this year, especially those aiming at going public in the first quarter, have delayed their ...

Monday saw more chaos and confusion on Wall Street. The Dow Jones Industrial Average saw trading range from 36,705 to 39,198- a nearly 2,500-point swing after a report indicating Trump could be open ...

Biopharmaceutical initial public offerings (IPOs) saw an upturn in 2024, with 50 completed IPOs raising a total of $8.52 ...

With the public stock markets in a free fall after President Trump announced sweeping tariffs, two of the tech industry’s ...

Almost a dozen venture-backed startups are in different stages of going public in the current financial year. These include ...

Despite recent market volatility, several companies in India have shown renewed interest in IPOs, indicating market ...

Sign up for the India Edition newsletter by Menaka Doshi – an insider's guide to the emerging economic powerhouse, and the ...